8-K
filed April 3, 2026, 7:59 PM ET
ticker MTNB
CIK 0001582554
regulatory
confidence high
sentiment negative
materiality 0.85
Matinas BioPharma receives NYSE American delisting notice for low equity
Matinas BioPharma Holdings, Inc.
- Stockholders' equity was $4.83M as of Dec 31, 2025, below the $6M threshold for five years of losses.
- Company has until May 2, 2026 to submit a plan to regain compliance; cure period up to 18 months.
- Independent auditor included a going-concern paragraph in the 10-K for the year ended Dec 31, 2025.
- No immediate impact on listing; common stock continues trading on NYSE American pending review.
- If plan is rejected, delisting proceedings will commence; company may appeal per NYSE rules.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001493152-26-015170
- form_type
- 8-K
- ticker
- MTNB
- cik
- 0001582554
- company_name
- Matinas BioPharma Holdings, Inc.
- filed_at
- 2026-04-03T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.516721+00:00
- generated_at
- 2026-05-15T07:35:52.322086+00:00
- sec_items
- ["3.01", "9.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.85
- calibrated_materiality_score
- 0.85
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001493152-26-015170
- json_url
- https://secwatch.observer/filing/0001493152-26-015170.json
- markdown_url
- https://secwatch.observer/filing/0001493152-26-015170.md
- text_url
- https://secwatch.observer/filing/0001493152-26-015170.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1582554/000149315226015170/0001493152-26-015170-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1582554/000149315226015170/form8-k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ATNM
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
May 29, 2026, 5:10 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued
listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company
to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in
two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
Comparable filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Filing page
SEC filing
ONFO
Onfolio receives Nasdaq delisting notice for insufficient equity ($1.22M vs $2.5M min)
Onfolio Holdings, Inc
May 29, 2026, 4:30 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued
listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company
to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in
two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
Comparable filing
May 26, 2026, Onfolio Holdings Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Quarterly Report on Form 10-Q for the for the period ended March 31, 2026 reported stockholders’ equity of $1,216,603. As of the date of the Notice
Filing page
SEC filing
RR
Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing
RICHTECH ROBOTICS INC.
May 28, 2026, 4:49 PM ET
regulatory
Items 3.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued
listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company
to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in
two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
Comparable filing
May 22, 2026, Richtech
Robotics Inc., a Nevada corporation (the “ Company ”) received a notice (the “ Notice ”) from the Listing
Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company is not in compliance
with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”), because it has not timely filed its Quarterly Report on Form 10-Q
for the period ended March 31, 2026 (the “ Form 10-Q ”) with the U.S. Securities and Exchange Commission (the “ SEC ”). The
Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Com
Filing page
SEC filing
SONM
DNA X receives Nasdaq delisting notice; issues $3.05M convertible note to insider
DNA X, Inc.
May 27, 2026, 4:35 PM ET
regulatory
Items 1.01, 2.03, 3.01, 3.02, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued
listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company
to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in
two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
Comparable filing
May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests
a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting
Filing page
SEC filing
VSTD
Vestand receives Nasdaq delisting notice for late quarterly and annual filings
Vestand Inc.
May 26, 2026, 5:18 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued
listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company
to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in
two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
Comparable filing
May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying
it that Nasdaq has initiated a process which could result in the delisting of the Company’s secu
Filing page
SEC filing
XHLD
TEN Holdings receives Nasdaq equity deficiency notice; issues 500k shares for $500k
TEN Holdings, Inc.
May 26, 2026, 4:05 PM ET
regulatory
Items 1.01, 3.01, 3.02, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued
listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company
to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in
two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
Comparable filing
May 26, 2026, the Company received a deficiency letter from the Listing Qualifications Department (the “ Staff ”)
of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in compliance with Nasda
Filing page
SEC filing
NVVE
Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review
Nuvve Holding Corp.
May 22, 2026, 6:35 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued
listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company
to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in
two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
Comparable filing
May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company
Filing page
SEC filing
GITS
GITS receives Nasdaq delinquency notice for late Q1 10-Q and unfiled 2025 10-K
Global Interactive Technologies, Inc.
May 22, 2026, 5:29 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from
the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued
listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company
to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in
two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha
Comparable filing
May 21, 2026, Global Interactive Technologies, Inc. (the “ Company ”)
received a delinquency compliance alert notice (the “ Notice ”) from the Staff of the Listing Qualifications Department
(the “ Staff ”) of The Nasdaq
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.